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The etfects oftwo calcium channel blockers, diltiaxem (270 
mg/day) and verapamil (240 mg/day), were studied in 18 
patients with chronic atrial fibrillation. During 24 b Walter 
electrocardiographic monitoring, mean ventricular ate 
(beats/n&t) decreased from 88 f 14 with placebo to 76 + 13 
(p < 0.001) with diltiaxem and 80 f 11 (p < 0.01) with 
verapamil. Maximal symptom-limited exercise tolerance 
(W) increased from 127 f 39 during the placebo period to 
136 + 42 (p < 0.01) with diltiaxem and 137 f 39 (p < 0.01) 
with verapamil. 
Ventricular rate and rate-pressure product were lower 
at rest and during exercise with diltiaxem and verapamil 
than with placebo (p < O.OOl), with the drugs being 
similarly effective. Ventricular rate at maximal exercise 
Chronic atria1 fibrillation ischaracterized by a rapid increase 
in the ventricular rate during exercise (I). This may be 
detrimental o cardiac output because of impaired ventricu- 
lar diastolic filling (2). Digoxin alone, acting primarily by 
causing an increase in vagal tone, often fails to control 
exercise-induced tachycardia in patients with atrial fibrilla- 
tion (3). The calcium channel blockers diltiazcm and vera- 
pamil increase r fractoriness and prolong conduction time in 
the atrioventricular node. These agents may effectively 
decrease ventricular rate in atrial fibrillation both at rest and 
during exercise (4,5). Diltiazem isconsidered tohave a less 
negative inotropic effect (6), a possible advantage in the 
treatment of atrial fibrillation. 
One study (7) reported a substantial improvement in
exea:ise capacity in patients with chronic atrial fibrillation 
after the administration f verapamil. Inother investigations 
(8-lo), neither diltiazem nor verapamil was reported to 
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(beats/mitt) was 179 f I3 with placebo compar 
+ 21 with diltiaxeln and 158 f 23 with verapamt 
oxygen uptake (ml/kg per min) was 22. 
placebo, 23.7 f 4.9 (p < 0.05) 
4.5 with verapamil (p = NS). 
anaerobic threshold was reached at a work load (WV) of 76 
= 21 with placebo, 84 f 27 (p C 0.05) with diltiaxem and 
85 f 23 (p c 0.01) with verapamil. 
In conclusion, patients with chronic atrial fibr 
have modestty improved exercise tolerance with calcium 
channel blockade therapy. The dromotropic responses aud 
the effects on physical performance are of similar magni- 
tude for diltiaxem and verapamil. 
(J Am Coil Cardiol1990;16:86-90) 
change xercise tolerance. A direct comparison of the two 
drugs, including as exchange analysis, has to our knowl- 
edge, not been performed. 
The aim of this study was to compare the effects of 
diltiazem and verapamil on ventricular rate response, max- 
imal exercise tolerance and gas exchange variables during 
exercise in patients wi h chronic atrial fibrillation. 
Study patients. Nineteen patients (13 men and 6 women, 
mean age 65 2 5 years, range 55 to 74) with atrial fibrillation 
for 21 month (defined in this study as chronic atrial fibrilla- 
tion) were included after providing informed consent. One 
patient did not complete he study protocol; thus, the results 
are obtained from 18 patients. Eleven of the 18 had lone 
atrial fibrillation, and 5 had one or more underlying cardio- 
vascular disorders, including mitral stenosis (n = l), surgi- 
cally corrected mitral stenosis (n = I), hypertension (  = 3), 
ischemic heart disease (n = 1) and left heart failure (n = 1). 
Two patients had mild chronic bronchitis. All patients were 
in New York Heart Association functional class I or II. 
Seventeen patients were t ated with digoxin (0.13 [n = 31 
and 0.25 mg [n = 141 daily). All antiarrhythmic drugs were 
discontinued before the start of the study. 
073s1097190/83.50 
after the last dose 
liter, and concentrations below 
de~a was 
every 6 s, with the KG csntinuously 
test. Ventricular rate was determined by m~lti~lyj~g the 
number af QRS complexes per 30 s by 2. Blood pressure 
rn~asur~rn~~ts wereQbtai~ed using a s~bygm~ma~~meter 
and a ~~~~ler device to record the pulse in the radial artery, 
The patient’s ubjective perceptive of ~xe~i~~ was evalu- 
ated by using the Borg 6 ta 20 point scale (I4). 
Respiratory gas exchange variables were determined 
continuously throughout the exercise test using the Medical 
~~~hi~s Corporation 2001 system. The analyses ineluded 
u~~gen uptake (ml/kg per main), minute ventilati~m ~liters~ 
min) and respiratory exchange ratio (carbon dioxide elimi- 
nation/oxygen uptake). The data were processed by au 
average filter, and mean values over I5 s intervals were 
estimated, Points of analysis were at 50% and 80% of the 
m~imal work load achieved uring placebo treatment and at 
rn~irn~ exertion. The gas exchange anaerobic threshold 
determined as outlined by Beaver et al. (Is) was taken as the 
mean nf estimations performed by two independent observ- 
ers who were unaware of other patient data, 
istlcs, Data are presented as tke mean value +- §IX 
Because the study had a Passover design, the rnai~ statis- 
tical taol was analysis of variance for repeated measure- 
ments. The analysis was completed with paired t tests or 
appropriate nonparametric ests. If not stated otherwise, the 
values given nkr 10 e comparison between either oft 
and go rf: 11 beats~mi~ 
< 0.01) with verapamil. Comparing ventricular rate at 
ting rest and during exerci active treatment re 
diltia~em sod vera 
and 858 5 23 beatslmin with verapamil. 
Systolic hload pressuw (Fig. 3) was somewhal Iower 
during active treatment, but similar for diltiazem and vera- 
pamil. The must prQnou~~ed d crease was seen at 80% work 
lacebca 193 sr: 22, d~lt~a2em 18$ 2 22 f 
verapamil 182 -k 34 mm IIg [p < o.oa1g. 
Figwe 2. Ventricular rates during sitting (rest), at submaximat work 
loads ~orr~s~~di~g to 50% and 80% of maximum during the 
placebo phase and at the m~~irnal work load (Max) attained du~~g 
each treatment. **p < OAW. ?ii: = mean. 
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Figure 3. Systolic blood pressure (SBP) while sitting (rest) snd 
during exercise, lp < 0.05; ““p < 0.01. Other symbols and explana- 
tions as in Figure 2. 
Rate-pressure pruduct WQS sign&antly decreased (p < 
0.001) at sitting rest and during all stages ofexercise when 
comparing active treatment and placebo, but without any 
difference between diltiazem and verapam& 
Exercicse ~~. The maximal wurk lsad attained ur- 
ing placebo treatment was 127 f 39 W. Exercise tolerance 
increased ta 136 -C 42 W (p < 0.01) during diltiazem and 
137 +- 39 W (p < 0.01) during verapamil treatment. Maximal 
perceived exertion was 19.1 + 0.3,19.3 -C 0.7 and 19.2 + 0.8 
points on the Borg scale, respect~veIy (p = NS), 
~~~i~t~~y ~a~~~ Oxygen uptake {Fig. 4) during 
different reatments was similar at submaximal exercise 
levels. Maximal oxygen uptake during placebo treatment 
was 22.3 * 4.5 ml/kg per min; the corresponding values for 
diltiazem and verapamil were 23,7 f 4.9 (p < 0.05) and 22.9 
2 4S (p = NS), respectivefy. The digerence between the 
two drugs was not significant (p= 0.074). 
Minute ventilation was also simikr at s~~btnnximul work 
Figure 4, Oxygen uptake rVC&) during exercise. Symbols 
exp~~ati~~s as in Figures 2 and 3. 
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Table 1. Serum Digoh ~o~ce~trati~~s {nrno~jte~~ 
Digoxin Placebo Diltiazem VerapamiJ 
CO.6 8 6 4 
0.6-l .o 6 8 8 
>I.0 3 3 5 
Data re derived from 17 of the 18 patienls receiving digoxin; there was no
significant difference b tween treatments. 
faads dmkg all ~~e~~~?e~t perimls. The maximal v~~t~~at~on 
was 69 * 21 for placebo, 75 f 26 (p = NS) for d~~t~azern and 
74 2 23 literslmin (p = NS) for verapamil. 
Respirarovy exchange ratio. The response pattern was 
the same as for other espiratory variables. Mslximal values 
attained were 1.13 + 0.08 with placebo, 1.15 i: 0.1 I (p = NS) 
with diltiazem and I+ t6 + 0.11 (p = NS) with verapamil. 
The u~a#~ab~~ th~eshu~d could nut be det~~~ued im one 
patient with chronic bronchitis and during one test in another 
patient because of air leakage from the mouthpiece. Values 
were compared among the 16 patients in whom complete 
data were obtained. The correlation between the two observ- 
ers was r = 0~9gO. 
During tke placebo pericrd, the tritevia far the gas ex- 
chnnge anaerobic threshold were met at a work load of 76 -I- 
21 W (60 -C 17% of maximum), corresponding to an oxygen 
uptake of 16.2 -t 2.4 ml/kg per min. The corresponding 
values were 84 +- 27 fp -C ~.O~, 62 + 20% of rn~xirn~rn~ 
and 16.9 C 3.0 ml/kg per min for diltiazem and 85 1 23 W 
(p < O.OI,42 1: 17% of maximum) and 16.6 or: 3.0 ml/kg per 
min for verapamil. 
Drug concentrations. TRe distribution of serum digoxin 
con~entrat~ous during the different treatments is shown in 
Table t. Plasma dilt~~em ~on&ent~tjon was 453 f: 184 ng!ml 
(range 57 to 757); the corresponding value for plasma vera- 
pamil was 175 5~ 107 @ml (range 36 to 495). 
Side eflects. The withdrawal of ne patient was due to 
ankle edema during the second treatment period (diltiazem). 
All other suspected side effects are listed inTable 2. 
Tabk 2. Number ofSide Effects in 18 Patients 
Ankle edema 
Fatigue 
Dizziness 
Constipation 
Flat~e~c~di~~~ea 
Headache 
Other 
Total 
Placebo Diltiazem Verapamil 
4 8 8 
4 6 8 
4 4 3 
t 3 b 
3 2 4 
2 4 2 
7 9 IO 
25 36 41 
exercise. Verapamil nterac 
changes in serum digoxin in 
and, thus, should not affect h comparisons among treat- 
ments. The influence of diltiaz 
ular rate was of the same mag 
the maximal exercise toler- 
ance by 7% to 8%. It may be argued t at the patients bet 
accustomed tothe testing procedu after the first test 
that this contributed to e improvement i  th 
tests. Still, the perceive exertion was unahe 
work loads, including th aximal work load, 
only a small insignificant change in the maximal respiratory 
exchange ratio. The delayed response in gas exchange 
anaerobic threshold is also consistent with a moderate but 
sponse to treatment varies considerably, which is easily 
appreciated from the upper and lower ranges indicated in 
Figures 2 to 4. Improved iastolic filling through ventricular 
rate reduction would be expected to affect cardiac output 
and exercise performance, preferably at high heart rates 
close to maximal exertion. Maximal oxygen uptake was. 
however, significantly increased only with diltiazem. Con- 
versely, the change in anaerobic threshold indicates an 
improved peripheral metabolic response to exercise for both 
drugs. The ventilator-y anaerobic threshold is a reproducible 
index of the increase in blood lactate (16,17), and a delay in 
this point is seen after physical training both in normal 
subjects and in patients with chronic heart failure (i&19). 
Previous exercise testing in patients with chronic atrial 
fibrillation on calcium channel blocker therapy has yielded 
divergent results (7-10). The lack of improvement i  exer- 
cise capacity in two studies of diltiazem (8.9) may have been 
due to an excessive lowering of maximal heart rate to 133 to 
142 beats/min. In the present investigation, heart rate was 
reduced from a high mean value of 179 to 159 beatslmin, 
which is close to the normal age-predicted maximal heart 
rate (20). An impressive increase in xercise capacity was 
between ve~trjc~~ar 
ta. The relation 
end on the inho- 
een suggested (21) that a high maximal heart rate 
on is of minor importance athigh heart rates. 
sumed that after ventricular rate reduction, 
possible negative inotropic effects of the calcium channel 
to be cou,,teracted by a tive Frank- 
A negative drug effect ca an earher- 
robic threshold and a lower maximal oxygen 
. In chronic atrial fibrihation, such a response is 
ed by the beta-blocker celiprolol (23). No consistent 
found between diltiazem 
these respects; hence, it seems that any di 
tive inotropy of the two drugs is 
given in doses with comparable negative dromotropic re- 
sponses. The conformity of the effects on systolic blood 
pressure also suggest imilar vasodilating properties. These 
results are in contrast to findings in experimental studies 
(24.25) in which verapamil caused more potent negative 
inotropic and dromotropic effects when the drugs were 
administered in equihypotensive doses. 
ications. Chronic atria! fibrillation is often 
and may precede congestive heart failure 
(26,27). This association is found even in the absence of 
other overt cardiovascular disease. Myocardial energy de- 
pletion, which is promoted by a high myocardial work load, 
has been suggested as an important factor in the develop- 
ment of heart failure (28). Calcium channel blockers may 
interfere in this process in patients with chronic atrial 
fibrillation, because the rate-pressure product is reduced 
substantially b treatment with diltiazem and verapami!. GS 
a consequence, myocardial oxygen consumption and energy 
demand are reduced. Importantly, this is achieved without 
’ compro ‘ng cardiocirculatory function. 
Side es. As indicated inTable 2, typical side effects 
of calcium channel blockers (for example. edema and con- 
stipation) were more frequent during active treatment. These 
side effects are known to be dose dependent (4,lO). para- 
doxically, fatigue was reported by some patients despite 
increased exercise capacity. This may relate to excessive 
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ventricular rate reduction at rest. Taken together, these 
observations emphasize the need for individual dose titra- 
tion. 
Conclusions. Diltiazem and verapamil are both effective 
agents in the treatment ofpatients with chronic atria1 fibril- 
lation. The negative dromotropic effect and the influence on 
exercise performance do not seem to diier when the two 
drugs are administered in the present dosage. 
We acknowledge Anna-Lena E:son-Loft for help in preparing the manuscript 
and &ten Karlsson for technical assistance. 
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